QXQiaobing Xu

Qiaobing Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qiaobing Xu has a total of 287 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Silk‐Based Protein Corona Enhances mRNA‐LNP Vaccine Efficacy and Prevents Tumor Relapse

    by Shangyuan Cui, Zhongfeng Ye, Mariah L. Arral, Lihan Liu, Benson Weng, Xiaohan Zhang, Remya Nair, Yuchen Zhao, Jugal Kishore Sahoo, Shuliang Gao, et al.

    Lipid nanoparticles (LNPs) are clinically validated carriers for nucleic acid therapeutics; however, achieving targeted delivery to reticuloendothelial organs beyond the liver, lung, and spleen remains a major challenge. Here, we introduce a strategy for post‐fabrication engineering of a custom protein corona on mRNA‐LNPs using cationic silk fibroin (SF), a biocompatible and chemically tunable protein polymer. SF‐coated LNPs exhibit enhanced cellular uptake and endosomal escape, resulting in a 3.6 fold increase in lymph node delivery and a 2.5 fold extension in in vivo protein expression compared to unmodified LNPs. In a cancer vaccine model, SF‐LNPs significantly improve dendritic cell maturation, antigen cross‐presentation, and cytotoxic T cell activation, leading to robust protection against tumor growth and metastasis, as well as durable immunological memory. This work expands the formulation space for LNPs and establishes silk fibroin as a modular surface engineering tool for enhancing the efficacy and specificity of mRNA‐based therapeutics.


  • Human blood–brain barrier tissue model to characterize lipid nanoparticle delivery and transport mechanisms

    by Xiaohan Zhang, Zhongfeng Ye, Shangyuan Cui, Taisia Shmushkovich, Hiroaki Tani, Ying Chen, Marly Coe, Artem Arkhangelskiy, Mariah L. Arral, Maria G. Savvidou, et al.


  • Spatial Conformation of Ionizable Lipids Regulates Endosomal Membrane Disruption

    by Yu Zhao, Zhiyuan Qu, Markéta Paloncýová, Zeyu Wang, Benson Weng, Yuchen Zhao, Lihan Liu, Donghui Song, Douglas Wich, Michal Otyepka, et al.

    The delivery efficiency of biologics via lipid nanoparticles (LNPs) is critically dependent on the incorporation of ionizable lipids. The subtle structural changes to these lipids led to dramatic variations in cytosolic delivery efficiency. However, beyond the pKa values of tertiary amines in ionizable lipids, our understanding of the structure-activity relationships (SARs) between ionizable lipid spatial conformations and their endosomal escape efficacies remains limited. Here, we constructed a library of 18 bioreducible ionizable lipids with varying numbers of alkyl tails, ranging from two to four. We found that three-tailed ionizable lipids exhibited robust endosomal disruption and cytosolic delivery efficiency compared to those of their counterparts with similar pKa values. Molecular dynamics simulations and 31P NMR spectroscopy show that the three-tailed ionizable lipid adopts a characteristic cone-shaped structure, which upon interaction with endosomal phospholipids promotes the formation of inverted hexagonal phases and facilitates endosomal membrane disruption. These results underscore that the number of alkyl tails in ionizable lipids must be precisely tuned, as excessive tail branching may not linearly correlate with improved endosomal disruption. Our research contributes to the mechanistic comprehension of ionizable lipids, highlighting that the spatial configuration serves as a critical design parameter governing intracellular biologic transport.


  • Open Access

    Improving adenine base editing precision by enlarging the recognition domain of CRISPR-Cas9

    by Shuliang Gao, Benson Weng, Douglas Wich, Liam Power, Mengting Chen, Huiwen Guan, Zhongfeng Ye, Chutian Xu, Qiaobing Xu

    Domain expansion contributes to diversification of RNA-guided-endonucleases including Cas9. However, it remains unclear how REC domain expansion could benefit Cas9. In this study, we identify an insertion spot that is compatible with large REC insertion and succeeds in enlarging the non-catalytic REC domain of Streptococcus pyogenes Cas9. The natural-evolution-like giant SpCas9 (GS-Cas9) is created and shows substantially improved editing precision. We further discover that enlarging the REC domain could enable regulation of the N-terminal adenine deaminase TadA8e tethered to the Cas9 scaffold, which contributes to substantially reducing unexpected editing and improving the precision of the adenine base editor ABE8e. We provide proof of concept for evolution-inspired expansion of Cas9 and offer an alternative solution for optimizing gene editors. Our study also indicates a vast potential for engineering the topological malleability of RNA-guided endonucleases and base editors.


  • Open Access

    In vivo base editing of Angptl3 via lipid nanoparticles to treat cardiovascular disease

    by Jennifer Khirallah, Hanan Bloomer, Douglas Wich, Changfeng Huang, J. Noah Workman, Yamin Li, Gregory A. Newby, David R. Liu, Qiaobing Xu


  • Open Access

    ZUGC-RNA degradation generates immunosuppressor to evade immune responses in eukaryotes

    by Shuliang Gao, Mengting Chen, Douglas Wich, Hanan Bloomer, Zhiyuan Qu, Huiwen Guan, Qiaobing Xu

    Among the hundreds of modified nucleosides identified in terrestrial life, 2-amino-6-aminopurine (Z) is widely recognized as a prominent modified purine. Recently, RNA written with the ZUGC alphabet shows significant potential in RNA therapeutics as a synthetic biosystem. Here, we demonstrate that ZUGC-RNA can evade immune recognition in eukaryotes, independent of factors such as RNA length, sequence, 5’-triphosphate, modified uridine, and secondary structure. Notably, we discovered that both the degradation of ZUGC-RNA and metabolites of Z-nucleotides can function as immunosuppressors, silencing TLR7 sensing to block immune responses. This mechanism differs from that of pseudo-uridine (Ψ) modified RNA currently in use. ZUGC-RNAs also demonstrate broad applicability across multiple neural cell types. Our findings provide valuable insights for developing more tolerable RNA-based drugs and designing immunomodulators targeting TLR7. In addition to the potential prebiotic relevance of Z, our finding not only contributes to understanding the RNA world hypothesis but also provides new insights into the exploration of the origin of life.


  • Antitumour vaccination via the targeted proteolysis of antigens isolated from tumour lysates

    by Yu Zhao, Donghui Song, Zeyu Wang, Qingqing Huang, Fan Huang, Zhongfeng Ye, Douglas Wich, Mengting Chen, Jennifer Khirallah, Shuliang Gao, et al.

    The activation of cytotoxic T cells against tumour cells typically requires the cross-presentation, by antigen-presenting cells (and via major histocompatibility complex class I molecules), of an epitope derived from a tumour antigen. A critical step in antigen processing is the proteolysis of tumour antigens mediated by the ubiquitin–proteasome pathway. Here we describe a tumour vaccine leveraging targeted antigen degradation to augment antigen processing and cross-presentation. Analogous to proteolysis-targeting chimaeras, the vaccine consists of lymph-node-targeting lipid nanoparticles encapsulated with tumour antigens pre-conjugated with ligands that can bind to E3 ubiquitin ligases. In mice with subcutaneous human melanoma or triple-negative breast cancer, or with orthotopic mouse Lewis lung carcinoma or clinically inoperable mouse ovarian cancer, subcutaneously delivered vaccines prepared using tumour lysate proteins elicited antigen-specific adaptive immunity and immunological memory, and inhibited tumour growth, metastasis and recurrence, particularly when combined with immune checkpoint inhibition.


  • Tuning Lipid Nanoparticles for RNA Delivery to Extrahepatic Organs

    by Donghui Song, Yu Zhao, Zeyu Wang, Qiaobing Xu

    RNA therapeutics have been successfully transitioned into clinical applications. Lipid nanoparticles (LNPs) are widely employed as nonviral delivery vehicles for RNA therapeutics in commercial vaccine and gene therapy products. However, the bottleneck in expanding the clinical applications of LNP‐based RNA therapeutics lies in the tendency of these nanoparticles to preferentially accumulate in the liver. This challenge underscores the need to design LNPs capable of delivering RNA to organs beyond the liver. In this perspective, recent progress is discussed in developing strategies for designing LNPs to deliver RNA to extrahepatic organs. Organ‐selective targeting capability is achieved by either altering the composition of the LNP formulation or chemically modifying the ionizable lipid component. Both approaches result in changes in the physicochemical properties of the LNPs, which subsequently alters the composition of the biomolecular corona that adsorbs onto its surface following administration. The biomolecular corona is a known mechanism that mediates organ‐selective LNP delivery. Furthermore, this perspective aims to provide an outlook on shaping the next‐generation LNP delivery platforms. Potential efforts include targeting specific cell types, improving the safety profile of LNPs, and developing strategies to overcome physiological barriers against organ‐specific delivery.